Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Hepatology. 2015 Dec 21;63(2):428–436. doi: 10.1002/hep.28327

Figure 2. Probabilistic Sensitivity Analysis of Treatment Strategies for Treatment-Naïve Genotype 1 Hepatitis C Cost-Effective in >5% of Iterations.

Figure 2

Note: F3 and F4 – METAVIR stages of hepatic fibrosis, 3D – ombitasvir, ritonavir, paritaprevir, dasabuvir ribavirin, SOF/LDV – sofosbuvir/ledipasvir. Strategies that were cost-effective in <5% of iterations are not depicted. These strategies included: treating all with the previous standard of care, treating when F4 with 3D, treating when F3/F4 with 3D or SOF/LDV, staged treatment of F3/F4 first with SOF/LDV, and staged treatment of F4 first with 3D or SOF/LDV.